Reniguard Life Sciences Inc.
A biotech company
Monday, February 11, 2013
Embassy Suites, Chesterbrook, Pennsylvania (directions)
|
About
|
Reniguard's R&D in Early Detection
Although the past two decades have seen remarkable advances in the development of oncological therapeutics and personalized cancer treatments, early detection/diagnosis remains the most effective way of saving lives. Reniguard is developing mutation assays for the early detection and risk assessment of certain cancers. Reniguard is also developing assays for the early diagnosis of drug-resistance during treatment of chronic hepatitis B.
Technical Innovations
Cancer is a genetic disease caused by mutations or a combination of mutations with epigenetic modifications. These cancer-derived genetic materials, when detected from body fluids (blood, urine, etc), can provide useful information for cancer risk assessment, early diagnosis, post-surgery monitoring and prognosis purposes. However, this requires the detection methods to be ultra-sensitive and preferably quantitative. Body fluids contain normal non-mutated DNAs which suppress the detection of mutated DNAs. As the amount of mutated DNAs is very little compared with the amount of normal DNAs at the early stage, detecting mutated DNAs is like finding "a needle in a haystack" . Scientists at Reniguard have developed mutation detection technologies that have detection sensitivities as high as 0.1 - 0.001%. This level of sensitivity makes early detection possible. They also have strong expertise in other aspects of assay development that are crucial to early detection.
3 Major Issues
|
-
To be successful, Reniguard believes it needs a strong business partner. How should Reniguard go about finding a CEO/business development partner when we don't have significant funding in hand?
-
Reniguard believes a solid market analysis is essential to establishing a defensible company valuation which will be critical to attracting potential investors. How can we perform or obtain a detailed market analysis with limited financial resources?
-
Reniguard Life Sciences is seeking non-dilutive funding through SBIRs, but we also need to understand how and when to attract private investment. How can we use non-dilutive financing to attract private investors? Who should we target? And what will it take to bring private funding on board?
Program:
|
6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)
8:00 - David Ren MD PhD, CSO of Reniguard, will deliver the Company's "Elevator" Pitch to the Group
8:20 - A Panel will address 3 Major Issues for the Company
9:00 - Open discussion: members and guests
<Top of the page>
|
 |
|
Slides
Audio
Video
Webcast
